BASKHANBIOPharma바스칸바이오제약
354390 · KONEX · ₩354390 · 바스칸바이오제약
- Market cap
- ₩25B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−42.6% from the high
₩2,860Today: ₩3,495 – ₩3,495₩6,090
Returns
- 1W−2.8%
- 1M−0.1%
- 3M−10.2%
- 6M−29.9%
- YTD−26.9%
- 1Y−35.3%
- Volume today
- 1
- 0.0× the 20-day average
- Traded today
- ₩3,495
- Listed shares
- 7,018,247
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+5.8% on Oct 29, 2026.
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 28 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is above its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
BASKHANBIOPharma stock overview
BASKHANBIOPharma (바스칸바이오제약, KRX: 354390) is listed on KONEX, in the Biotech & Pharma sector. Baskan Biopharm is a South Korean company that manufactures and sells prescription and over-the-counter pharmaceuticals as well as medical devices. Its shares closed at ₩3,495 on Oct 29, 2026, up 5.75% on the day, giving it a market value of ₩25B.
Key facts
- Market cap
- ₩25B
- Sector
- Biotech & Pharma
- Latest price change
- +5.75%
- As of
- Oct 29, 2026
- Main business
- Baskan Biopharm is a South Korean company that manufactures and sells prescription and over-the-counter pharmaceuticals as well as medical devices.
Quick answers about BASKHANBIOPharma
- What does BASKHANBIOPharma do?
- Baskan Biopharm is a South Korean company that manufactures and sells prescription and over-the-counter pharmaceuticals as well as medical devices. It focuses on products used before and after surgery, and it plans to expand its portfolio with non-reimbursed drugs, injectables and a hemostatic device. The company operates manufacturing facilities in Korea, including plants in Anseong, and its main products are prescription drugs, which accounted for about 72% of 2025 sales.
- What is the market cap of BASKHANBIOPharma?
- The market capitalisation of BASKHANBIOPharma was ₩25B at the close on Oct 29, 2026.
- Who are the largest shareholders of BASKHANBIOPharma?
- According to the latest official filings, the largest reported holders are Lee Beop-pyo (22.23%, as of Mar 30, 2026); Min Cheon-gi (0.19%, as of Sep 1, 2025).
- When is the next earnings report from BASKHANBIOPharma?
- Korean companies rarely announce results dates in advance. Based on when BASKHANBIOPharma filed the same report in past years, its next annual results is expected around Mar 18, 2027.
Company profile
Baskan Biopharm is a South Korean company that manufactures and sells prescription and over-the-counter pharmaceuticals as well as medical devices. It focuses on products used before and after surgery, and it plans to expand its portfolio with non-reimbursed drugs, injectables and a hemostatic device. The company operates manufacturing facilities in Korea, including plants in Anseong, and its main products are prescription drugs, which accounted for about 72% of 2025 sales.
Written by AI from the company's latest annual report.
- Korean name
- 바스칸바이오제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 이법표
- Founded
- Mar 1986
- Listed
- Jul 2022
- Listed shares
- 7,018,247
- Fiscal year ends
- Month 12
- Website
- www.baskhanbio.com
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent filings
See all- Change in Designated Adviser Appointment AgreementSep 28, 2026
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]Aug 31, 2026
- Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation BodiesAug 13, 2026
- Investor relations (IR) eventJul 3, 2026
- Investor relations (IR) eventJun 18, 2026
Titles in Korean until English translations are added.
Also known as: BASKHANBIOPharma / 바스칸바이오제약 / 354390 / KRX:354390
Source: KRX statistical information